MagForce AG to participate in nine upcoming international conferences in H2 2018
Published: Sep 10, 2018
Berlin, Germany and Nevada, USA, September 3, 2018 -- MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced its participation in nine upcoming scientific and investor conferences in the second half of 2018:
- Geman Fall Conference
Date: September 3-4, 2018
Location: Frankfurt, Germany
Presentation: Christian von Volkmann, CFO of MagForce AG, Tuesday, September 4, 2018
- Goldman Sachs European Medtech and Healthcare Conference
Date: September 5-6, 2018
Location: London, UK
Presentation: Ben J. Lipps, CEO of MagForce AG, Thursday, September 6, 2018
- Berenberg & Goldman Sachs Seventh German Corporate Conference
Date: September 24-26, 2018
Location: Munich, Germany
Presentation: Ben J. Lipps, CEO of MagForce AG, Tuesday, September 25, 2018
- 13th Meeting of the European Association of Neuro-Oncology (EANO 2018)
Date: October 10-14, 2018
Location: Stockholm, Sweden
- 18th European Congress of Neurosurgery (EANS 2018)
Date: October 21-25, 2018
Location: Brussels, Belgium
Booth: No. 12
Lunch Symposium: “Local Therapies For Malignant Gliomas”
Speakers: Prof Dr Walter Stummer, Director of the Department of Neurosurgery at the University Hospital Muenster, Germany;
Colin Watts, MD PHD, University of Birmingham, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, Birmingham, Great Britain
Date & Time: Golden Hall, Tuesday, October 23, 2018; 1.15-2.15pm CEST
- MEDICA 2018
Date: November 12-15, 2018
Location: Düsseldorf, Germany
Community booth: Berlin Partner für Wirtschaft und Technologie GmbH No. F 42, hall 15
- 23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO)
Date: November 15-18, 2018
Location: New Orleans, Louisiana, USA
- German Equity Forum 2018
Date: November 26-28, 2018
Location: Frankfurt, Germany
Presentation: Ben J. Lipps, CEO of MagForce AG, Tuesday, November 27, 2018
- Prior Capital Market Conference
Date: December 4, 2018
Location: Dreieich, Germany
Presentation: Barbara von Frankenberg, Vice President Communications & Investor Relations of MagForce AG, Tuesday, December 4, 2018
About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm®therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.
NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.
For more information, please visit: www.magforce.com.
Get to know our Technology: video (You Tube)
This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.
- End of Press Release -
Should you have any questions or would like to receive further information, please do not hesitate to contact us.
MC Services AG
phone: +49 211 529252 28
fax: +49 211 529252 29
MC Services AG
Handelsregister/Commercial Register: Amtsgericht Augsburg HRB 2117
Vorstand/Management Board: Raimund Gabriel, Anne Hennecke
Aufsichtsrat/Supervisory Board: Johannes Gabriel (Vorsitzender/Chairman)
This message may contain confidential and/or privileged information. If you are not the addressee or authorized to receive this for the addressee, you must not use, copy, disclose or take any action based on this message or any information herein. If you have received this message in error, please advise the sender immediately by reply e-mail and delete this message. Thank you for your cooperation.
If you wish to be removed from the MagForce distribution list, please click here.
In accordance with the new EU General Data Protection Regulation (GDPR), we ask for your consent to continue sending you press releases and other information. If we do not receive any feedback from you, we will continue to send you press releases in the future. You can revoke your consent to receive information and to store data at any time and without giving reasons by e-mail to firstname.lastname@example.org.